An Obesity Medicine Doctor Explains What GLP-1 Drugs Actually Do to Your Metabolism
Dr. Spencer Nadolsky is one of the most credible voices in obesity medicine on the internet. He is board-certified in both obesity medicine and family medicine, he treats patients daily, and he has been outspoken about the science behind GLP-1 drugs since before they became a mainstream cultural phenomenon. His talk at the Metabolic Health Summit digs into the metabolic changes that these drugs produce beyond the number on the scale, and it is the kind of presentation that separates clinical understanding from the oversimplified narratives you see on social media.
The central point of his talk is that weight loss is not the whole story. GLP-1 drugs produce metabolic improvements that go beyond what you would expect from the weight loss alone. This is an important distinction because it means the drugs are doing more than just making people eat less. They are changing how the body processes energy, handles blood sugar, stores and burns fat, and manages inflammation at a cellular level. Understanding these effects gives both patients and physicians a more complete picture of what the medication is actually doing.
To put it another way: if you gave someone a calorie-restricted diet that produced the same amount of weight loss as semaglutide, you would not see identical metabolic improvements. The drug is producing effects that pure caloric restriction does not produce. That observation has significant implications for how we think about obesity treatment and whether these medications are addressing the root physiology of the disease rather than just its most visible symptom.
Insulin Resistance and the GLP-1 Effect
Dr. Nadolsky starts with insulin resistance because it is the metabolic dysfunction at the center of obesity-related disease. When cells become resistant to insulin's signal, the pancreas compensates by producing more insulin. This hyperinsulinemia drives fat storage, promotes inflammation, increases triglyceride production, and eventually overwhelms the pancreas, leading to type 2 diabetes. It also creates a hormonal environment that makes further weight gain almost inevitable and weight loss extremely difficult.
GLP-1 drugs improve insulin sensitivity through multiple pathways. The direct effect is enhanced insulin secretion in response to glucose (called glucose-dependent insulinotropic action). This means the drug helps your pancreas respond more appropriately to meals without the risk of hypoglycemia that comes with older diabetes drugs that force constant insulin release. The indirect effects come through weight loss, visceral fat reduction, decreased hepatic fat (liver fat), and reduced systemic inflammation, each of which independently improves insulin sensitivity.
Dr. Nadolsky presents data showing that patients on semaglutide have measurably improved insulin sensitivity within 4 to 8 weeks of starting treatment, often before significant weight loss has occurred. This suggests a direct metabolic effect of the drug that is separate from its weight loss effects. By 6 months, the insulin sensitivity improvements are substantial: patients show lower fasting insulin levels, improved HOMA-IR scores (a measure of insulin resistance), and better glucose tolerance on oral glucose tests.
The practical implication is that many patients on GLP-1 drugs can reduce or eliminate other diabetes and metabolic medications. He shares clinical examples of patients who came off metformin, sulfonylureas, and even insulin after achieving adequate metabolic control on semaglutide. This medication simplification is a meaningful benefit that goes beyond weight loss, reducing pill burden, side effects, and the complexity of managing multiple drug interactions.
What Happens to Visceral Fat Specifically
Not all fat is the same, and Dr. Nadolsky spends time on a distinction that matters enormously for metabolic health. Subcutaneous fat (the fat under your skin that you can pinch) is relatively metabolically benign. Visceral fat (the fat packed around your organs inside the abdominal cavity) is metabolically active in harmful ways. It secretes inflammatory cytokines, disrupts hormone signaling, contributes to insulin resistance, and is strongly associated with cardiovascular disease risk independent of total body weight.
GLP-1 drugs appear to preferentially reduce visceral fat. Imaging studies using MRI and DEXA scans have shown that the proportion of weight loss coming from visceral fat is higher with GLP-1 treatment compared to equivalent weight loss from diet alone. This means that two patients who lose the same amount of total weight, one through semaglutide and one through calorie restriction, may end up with different metabolic profiles because the semaglutide patient lost more of the dangerous visceral fat.
Dr. Nadolsky connects this to the observation that some patients on GLP-1 drugs see dramatic improvements in blood pressure, triglycerides, and inflammatory markers even when their total weight loss is relatively modest (in the 5 to 10% range). Visceral fat loss can drive outsized metabolic improvements because that specific fat depot is so metabolically disruptive. You do not need to lose 20% of your body weight to get meaningful metabolic benefits if the weight you are losing is coming from the right place.
The Inflammation Connection
Chronic low-grade inflammation is a hallmark of obesity and metabolic disease. It is driven partly by visceral fat (which produces inflammatory signals) and partly by the metabolic dysfunction itself (hyperglycemia and hyperinsulinemia both promote inflammation). This inflammatory state contributes to atherosclerosis, insulin resistance, fatty liver progression, and even neurodegeneration. It is one of the reasons obesity increases risk for so many different diseases across different organ systems.
GLP-1 receptor activation has been shown to have direct anti-inflammatory effects in multiple tissue types. In the cardiovascular system, it reduces markers of endothelial inflammation. In the liver, it decreases inflammatory infiltration in fatty liver tissue. In the brain, it may reduce neuroinflammation, which is one proposed mechanism for the neurological benefits (reduced addiction behavior, improved mood) that some patients report.
Dr. Nadolsky presents CRP (C-reactive protein) data from his own patient population showing average reductions of 40 to 60% after 6 months of semaglutide treatment. CRP is a general marker of systemic inflammation, and reductions of this magnitude are associated with meaningful reductions in cardiovascular event risk. The CANTOS trial demonstrated that reducing inflammation independently of cholesterol lowering can prevent heart attacks and strokes, so the anti-inflammatory effects of GLP-1 drugs may be contributing to cardiovascular protection through a pathway that has nothing to do with weight loss per se.
Resting Metabolic Rate and the Adaptation Question
One of the most persistent concerns about GLP-1 weight loss is metabolic adaptation, the phenomenon where resting metabolic rate (RMR) drops more than expected after weight loss, making weight maintenance harder and regain more likely. This is the same metabolic adaptation that has been documented in contestants from weight loss reality shows and in studies of calorie-restricted diets. Your body defends its weight by burning fewer calories, and that defense can persist for years.
Dr. Nadolsky presents data suggesting that metabolic adaptation may be less severe with GLP-1 weight loss compared to equivalent weight loss through calorie restriction alone. The proposed explanation involves the drug's effects on muscle preservation and hormonal signaling. If GLP-1 patients retain more lean mass (particularly when combined with resistance training and adequate protein), their RMR drops less because muscle is the primary determinant of resting metabolic rate.
He is careful to note that this is an area of active research and that the data is not conclusive. Some studies show similar degrees of metabolic adaptation regardless of the weight loss method. Others show a GLP-1 advantage. The discrepancy may come down to whether patients are doing resistance training and eating enough protein, which would confound the drug-specific effect. His practical advice is not to rely on the drug alone to prevent metabolic adaptation, but to actively counteract it through the same strategies that work in any weight loss context: strength training and protein.
Putting It All Together for Patients
Dr. Nadolsky's overarching message is that GLP-1 drugs are doing more than suppressing appetite. They are modifying the metabolic environment that created and sustains obesity. They improve insulin sensitivity, preferentially reduce visceral fat, lower systemic inflammation, and may partially protect against the metabolic adaptation that undermines long-term weight maintenance. These are not secondary effects. They are central to why these drugs produce such broad health improvements across multiple organ systems.
For patients, the takeaway is that the benefits of GLP-1 therapy extend well beyond the number on the scale. Even if your weight loss is modest, the metabolic improvements may be substantial. Tracking metrics beyond weight, such as waist circumference, blood pressure, fasting glucose, HbA1c, triglycerides, and inflammatory markers, gives a more complete picture of what the medication is doing for your health. Weight is the easiest thing to measure, but it is not the most important thing to measure.
For prescribers, the message is that these drugs should be paired with lifestyle interventions that amplify their metabolic effects: resistance training to preserve lean mass, adequate protein intake to support muscle maintenance, and dietary patterns that reduce the metabolic load the drug is working to correct. The drug creates a window of opportunity where the body is more metabolically flexible and more responsive to lifestyle changes. Using that window wisely is what separates good outcomes from great ones.
If you are on a GLP-1 medication and your only metric of success is what the scale says, you are missing most of the story. Ask your doctor for a full metabolic panel. Track changes in your waist circumference. Pay attention to how your blood pressure, blood sugar, and energy levels change over the first 3 to 6 months. The scale is one data point. Your metabolic health is the whole picture, and these drugs are changing it in ways that were not possible with any single intervention before them.